Study nutrition changes from Palynziq in adults with PKU
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at how taking Palynziq affects your nutrition and health in people with phenylketonuria (PKU). You might benefit by getting careful monitoring while researchers learn how the medicine changes diet-related measurements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years old or older
- You have been diagnosed with PKU (either from newborn screening or later diagnosis)
- You can give permission (consent) for study tests and procedures
- You are prescribed Palynziq and are enrolled in the Palynziq REMS program
- If you join the substudy, you have already finished visit 2 of the main study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether following specific care guidelines for phenylketonuria (PKU) leads to better metabolic control (blood phenylalanine levels) and better patient well-being. You may be asked to complete questionnaires and follow the study plan while receiving the usual PKU treatment your clinic recommends.
This study tests whether a specific mix of large neutral amino acids (LNAAs) can help adults with classical PKU by lowering phenylalanine levels in the brain. It includes an MRI and PET scan to see how the treatment affects brain activity.
This study looks at how much protein people with PKU need. If you have PKU and are 18 or older, you may help researchers understand your body's protein needs better.
This study looks at how educational, social support, and nutrition help affect pregnancy outcomes and quality of life in women with PKU. It may help you better manage PKU-related needs before and during pregnancy.
This study tracks the long-term safety of Palynziq (pegvaliase) in people with PKU as they take the medicine over time. It may help you and other patients understand long-term side effects and whether Palynziq stays safe.
This study tests whether combining a drug called methotrexate with Palynziq (a treatment for PKU) can help control immune responses and improve treatment outcomes. It may be an option for adults with PKU who have never used Palynziq or who have not reached target blood levels after at least 24 weeks.
Hear when a new Phenylketonurias trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.